Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Dundee Corp T.DC.PR.D


Primary Symbol: T.DC.A Alternate Symbol(s):  DNDPF | DDEJF | T.DC.PR.B | DNDEF

Dundee Corporation is a Canada-based holding company. Through its operating segments, the Company is a mining- focused investor primarily engaged in acquiring mineral resource assets. Its segments include Corporate and Other Portfolio Holdings; Goodman & Company, Investment Counsel Inc.; Dundee Sustainable Technologies Inc.; United Hydrocarbon International Corp., and Dundee 360 Real Estate... see more

TSX:DC.A - Post Discussion

Dundee Corp > TauRx submits UK marketing authorisation application
View:
Post by Catscratch on Jul 01, 2024 10:51am

TauRx submits UK marketing authorisation application

New press release on TauRx website.

https://taurx.com/news-insights/taurx-submits-uk-marketing-authorisation-application-for-hmtm-as-a-treatment-for-alzheimers-disease
Comment by pierrelebel on Jul 01, 2024 9:51pm
Taking a look at Genting, owner of 20%+ of TauRx, their shares are basically unchanged in Malaysia. From discussion boards in Asia, folks seem unimpressed: "UK MHRA's final decision on CA is unlikely to be within 2024. We still have to file in more submissions which will take abt 5 to 6 months to complete it, followed by another 6 to 9 months for the regulator's final decision. FDA ...more  
Comment by Catscratch on Jul 02, 2024 11:10am
I'm not sure on timeline from here.  But if they get a response in 3 months or 1 year its all fairly nearterm.  I believe there has been a lot of meetings and communication with the regulator and advisors leading up to this submission.  So presumably they don't go ahead unless they see a clear path toward approval. The comments on India and generics is BS.  Tons of ...more  
Comment by TheCount11 on Jul 02, 2024 10:17am
Am I the only one concerned that Dundee will fumble the ball one the 1 yard line? I find it sad that Dundee management does not seem to know or value what they own. I could see someone who is better informed make a low ball offer for Dundee TauRx if they know the drug is near approval.  Company has been in Tau for a decade.  UK approval is right around the corner. Would love to see ...more  
Comment by Catscratch on Jul 02, 2024 10:58am
I share the same concern.  It makes sense to wait until the approval decision.  With approval my guess is TauRx will sell to a larger/global drug company or pursue an IPO.
Comment by TheCount11 on Jul 03, 2024 8:41am
Ideally IPO to realize the full value. I get the feeling people don't realize the size of the market vs treatment options.  I think if investors compared it to the cardio market they would get a sense.  Dundee is sitting on the biggest goldmine but doesn't have the patience to wait another year yet will invest in a jr miner that will take 5 - 8 years?!
Comment by Catscratch on Jul 03, 2024 11:24am
I saw a post on the Genting boards that approval in the UAE will come before UK.  And likely this year. UAE is not a massive market but if/when the dominos start to fall...
Comment by TheCount11 on Jul 04, 2024 3:18pm
Thanks for sharing!  My feeling is you know more than management...
Comment by Catscratch on Jul 05, 2024 12:44pm
I hope not.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities